Viral Vector Manufacturing for Gene Therapy refers to the specialized process of producing viral vectors, which are engineered viruses used to deliver therapeutic genetic material into patients' cells. This process involves several stages, including design, production, purification, and quality control, to ensure that the viral vectors are safe, effective, and compliant with regulatory standards.
Viral vector manufacturing is crucial for the development and delivery of gene therapies, which aim to treat genetic disorders, cancers, and other diseases by introducing, removing, or altering genetic material within a patient’s cells. The manufacturing process ensures that these therapies are safe, effective, and ready for clinical use.
The global Viral Vector Manufacturing for Gene Therapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The “Viral Vector Manufacturing for Gene Therapy Industry Forecast” looks at past sales and reviews total world Viral Vector Manufacturing for Gene Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Viral Vector Manufacturing for Gene Therapy sales for 2023 through 2029. With Viral Vector Manufacturing for Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector Manufacturing for Gene Therapy industry.
This Insight Report provides a comprehensive analysis of the global Viral Vector Manufacturing for Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector Manufacturing for Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector Manufacturing for Gene Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector Manufacturing for Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector Manufacturing for Gene Therapy.
United States market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Viral Vector Manufacturing for Gene Therapy players cover Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector Manufacturing for Gene Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
AAV
Lentivirus
Adenovirus
HSV
Others
Segmentation by Application:
Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
AAV
Lentivirus
Adenovirus
HSV
Others
Segmentation by Application:
Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
Lonza
Catalent
Charles River
Merck
SK pharmteco
Oxford Biomedica
AGC Biologics（MolMed）
Gene Universal
Polyplus (Sartorius)
CCRM
FUJIFILM Diosynth Biotechnologies
Biovian
Miltenyi Bioindustry
Aldevron
Takara Bio
Yposkesi
Genezen
Exthera
Flash Therapeutics
VIVEBiotech
FinVector
Eurogentec
VGXI
GenScript ProBio
EurekaBio
Obio Technology
GeneSail Biotech
VectorBuilder
WuXi ATU
Ubrigene
Porton Biologics
Pharmaron
PackGene Biotechnology
Hillgene
Asymchem
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Viral Vector Manufacturing for Gene Therapy Market Size 2019-2030
2.1.2 Viral Vector Manufacturing for Gene Therapy Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Viral Vector Manufacturing for Gene Therapy by Country/Region, 2019, 2023 & 2030
2.2 Viral Vector Manufacturing for Gene Therapy Segment by Type
2.2.1 AAV
2.2.2 Lentivirus
2.2.3 Adenovirus
2.2.4 HSV
2.2.5 Others
2.3 Viral Vector Manufacturing for Gene Therapy Market Size by Type
2.3.1 Viral Vector Manufacturing for Gene Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Viral Vector Manufacturing for Gene Therapy Market Size Market Share by Type (2019-2024)
2.4 Viral Vector Manufacturing for Gene Therapy Segment by Application
2.4.1 Vaccine Development
2.4.2 Gene Therapy
2.4.3 Academic Scientific Research Institution
2.4.4 Others
2.5 Viral Vector Manufacturing for Gene Therapy Market Size by Application
2.5.1 Viral Vector Manufacturing for Gene Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Viral Vector Manufacturing for Gene Therapy Market Size Market Share by Application (2019-2024)
3 Viral Vector Manufacturing for Gene Therapy Market Size by Player
3.1 Viral Vector Manufacturing for Gene Therapy Market Size Market Share by Player
3.1.1 Global Viral Vector Manufacturing for Gene Therapy Revenue by Player (2019-2024)
3.1.2 Global Viral Vector Manufacturing for Gene Therapy Revenue Market Share by Player (2019-2024)
3.2 Global Viral Vector Manufacturing for Gene Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Viral Vector Manufacturing for Gene Therapy by Region
4.1 Viral Vector Manufacturing for Gene Therapy Market Size by Region (2019-2024)
4.2 Global Viral Vector Manufacturing for Gene Therapy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Viral Vector Manufacturing for Gene Therapy Market Size Growth (2019-2024)
4.4 APAC Viral Vector Manufacturing for Gene Therapy Market Size Growth (2019-2024)
4.5 Europe Viral Vector Manufacturing for Gene Therapy Market Size Growth (2019-2024)
4.6 Middle East & Africa Viral Vector Manufacturing for Gene Therapy Market Size Growth (2019-2024)
5 Americas
5.1 Americas Viral Vector Manufacturing for Gene Therapy Market Size by Country (2019-2024)
5.2 Americas Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
5.3 Americas Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Viral Vector Manufacturing for Gene Therapy Market Size by Region (2019-2024)
6.2 APAC Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
6.3 APAC Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country (2019-2024)
7.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
7.3 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Viral Vector Manufacturing for Gene Therapy by Region (2019-2024)
8.2 Middle East & Africa Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Viral Vector Manufacturing for Gene Therapy Market Forecast
10.1 Global Viral Vector Manufacturing for Gene Therapy Forecast by Region (2025-2030)
10.1.1 Global Viral Vector Manufacturing for Gene Therapy Forecast by Region (2025-2030)
10.1.2 Americas Viral Vector Manufacturing for Gene Therapy Forecast
10.1.3 APAC Viral Vector Manufacturing for Gene Therapy Forecast
10.1.4 Europe Viral Vector Manufacturing for Gene Therapy Forecast
10.1.5 Middle East & Africa Viral Vector Manufacturing for Gene Therapy Forecast
10.2 Americas Viral Vector Manufacturing for Gene Therapy Forecast by Country (2025-2030)
10.2.1 United States Market Viral Vector Manufacturing for Gene Therapy Forecast
10.2.2 Canada Market Viral Vector Manufacturing for Gene Therapy Forecast
10.2.3 Mexico Market Viral Vector Manufacturing for Gene Therapy Forecast
10.2.4 Brazil Market Viral Vector Manufacturing for Gene Therapy Forecast
10.3 APAC Viral Vector Manufacturing for Gene Therapy Forecast by Region (2025-2030)
10.3.1 China Viral Vector Manufacturing for Gene Therapy Market Forecast
10.3.2 Japan Market Viral Vector Manufacturing for Gene Therapy Forecast
10.3.3 Korea Market Viral Vector Manufacturing for Gene Therapy Forecast
10.3.4 Southeast Asia Market Viral Vector Manufacturing for Gene Therapy Forecast
10.3.5 India Market Viral Vector Manufacturing for Gene Therapy Forecast
10.3.6 Australia Market Viral Vector Manufacturing for Gene Therapy Forecast
10.4 Europe Viral Vector Manufacturing for Gene Therapy Forecast by Country (2025-2030)
10.4.1 Germany Market Viral Vector Manufacturing for Gene Therapy Forecast
10.4.2 France Market Viral Vector Manufacturing for Gene Therapy Forecast
10.4.3 UK Market Viral Vector Manufacturing for Gene Therapy Forecast
10.4.4 Italy Market Viral Vector Manufacturing for Gene Therapy Forecast
10.4.5 Russia Market Viral Vector Manufacturing for Gene Therapy Forecast
10.5 Middle East & Africa Viral Vector Manufacturing for Gene Therapy Forecast by Region (2025-2030)
10.5.1 Egypt Market Viral Vector Manufacturing for Gene Therapy Forecast
10.5.2 South Africa Market Viral Vector Manufacturing for Gene Therapy Forecast
10.5.3 Israel Market Viral Vector Manufacturing for Gene Therapy Forecast
10.5.4 Turkey Market Viral Vector Manufacturing for Gene Therapy Forecast
10.6 Global Viral Vector Manufacturing for Gene Therapy Forecast by Type (2025-2030)
10.7 Global Viral Vector Manufacturing for Gene Therapy Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Viral Vector Manufacturing for Gene Therapy Forecast
11 Key Players Analysis
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Information
11.1.2 Thermo Fisher Scientific Viral Vector Manufacturing for Gene Therapy Product Offered
11.1.3 Thermo Fisher Scientific Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Thermo Fisher Scientific Main Business Overview
11.1.5 Thermo Fisher Scientific Latest Developments
11.2 Lonza
11.2.1 Lonza Company Information
11.2.2 Lonza Viral Vector Manufacturing for Gene Therapy Product Offered
11.2.3 Lonza Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Lonza Main Business Overview
11.2.5 Lonza Latest Developments
11.3 Catalent
11.3.1 Catalent Company Information
11.3.2 Catalent Viral Vector Manufacturing for Gene Therapy Product Offered
11.3.3 Catalent Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Catalent Main Business Overview
11.3.5 Catalent Latest Developments
11.4 Charles River
11.4.1 Charles River Company Information
11.4.2 Charles River Viral Vector Manufacturing for Gene Therapy Product Offered
11.4.3 Charles River Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Charles River Main Business Overview
11.4.5 Charles River Latest Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Viral Vector Manufacturing for Gene Therapy Product Offered
11.5.3 Merck Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Merck Main Business Overview
11.5.5 Merck Latest Developments
11.6 SK pharmteco
11.6.1 SK pharmteco Company Information
11.6.2 SK pharmteco Viral Vector Manufacturing for Gene Therapy Product Offered
11.6.3 SK pharmteco Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 SK pharmteco Main Business Overview
11.6.5 SK pharmteco Latest Developments
11.7 Oxford Biomedica
11.7.1 Oxford Biomedica Company Information
11.7.2 Oxford Biomedica Viral Vector Manufacturing for Gene Therapy Product Offered
11.7.3 Oxford Biomedica Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Oxford Biomedica Main Business Overview
11.7.5 Oxford Biomedica Latest Developments
11.8 AGC Biologics（MolMed）
11.8.1 AGC Biologics（MolMed） Company Information
11.8.2 AGC Biologics（MolMed） Viral Vector Manufacturing for Gene Therapy Product Offered
11.8.3 AGC Biologics（MolMed） Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 AGC Biologics（MolMed） Main Business Overview
11.8.5 AGC Biologics（MolMed） Latest Developments
11.9 Gene Universal
11.9.1 Gene Universal Company Information
11.9.2 Gene Universal Viral Vector Manufacturing for Gene Therapy Product Offered
11.9.3 Gene Universal Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Gene Universal Main Business Overview
11.9.5 Gene Universal Latest Developments
11.10 Polyplus (Sartorius)
11.10.1 Polyplus (Sartorius) Company Information
11.10.2 Polyplus (Sartorius) Viral Vector Manufacturing for Gene Therapy Product Offered
11.10.3 Polyplus (Sartorius) Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Polyplus (Sartorius) Main Business Overview
11.10.5 Polyplus (Sartorius) Latest Developments
11.11 CCRM
11.11.1 CCRM Company Information
11.11.2 CCRM Viral Vector Manufacturing for Gene Therapy Product Offered
11.11.3 CCRM Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 CCRM Main Business Overview
11.11.5 CCRM Latest Developments
11.12 FUJIFILM Diosynth Biotechnologies
11.12.1 FUJIFILM Diosynth Biotechnologies Company Information
11.12.2 FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing for Gene Therapy Product Offered
11.12.3 FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
11.12.5 FUJIFILM Diosynth Biotechnologies Latest Developments
11.13 Biovian
11.13.1 Biovian Company Information
11.13.2 Biovian Viral Vector Manufacturing for Gene Therapy Product Offered
11.13.3 Biovian Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Biovian Main Business Overview
11.13.5 Biovian Latest Developments
11.14 Miltenyi Bioindustry
11.14.1 Miltenyi Bioindustry Company Information
11.14.2 Miltenyi Bioindustry Viral Vector Manufacturing for Gene Therapy Product Offered
11.14.3 Miltenyi Bioindustry Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Miltenyi Bioindustry Main Business Overview
11.14.5 Miltenyi Bioindustry Latest Developments
11.15 Aldevron
11.15.1 Aldevron Company Information
11.15.2 Aldevron Viral Vector Manufacturing for Gene Therapy Product Offered
11.15.3 Aldevron Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Aldevron Main Business Overview
11.15.5 Aldevron Latest Developments
11.16 Takara Bio
11.16.1 Takara Bio Company Information
11.16.2 Takara Bio Viral Vector Manufacturing for Gene Therapy Product Offered
11.16.3 Takara Bio Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Takara Bio Main Business Overview
11.16.5 Takara Bio Latest Developments
11.17 Yposkesi
11.17.1 Yposkesi Company Information
11.17.2 Yposkesi Viral Vector Manufacturing for Gene Therapy Product Offered
11.17.3 Yposkesi Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Yposkesi Main Business Overview
11.17.5 Yposkesi Latest Developments
11.18 Genezen
11.18.1 Genezen Company Information
11.18.2 Genezen Viral Vector Manufacturing for Gene Therapy Product Offered
11.18.3 Genezen Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Genezen Main Business Overview
11.18.5 Genezen Latest Developments
11.19 Exthera
11.19.1 Exthera Company Information
11.19.2 Exthera Viral Vector Manufacturing for Gene Therapy Product Offered
11.19.3 Exthera Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Exthera Main Business Overview
11.19.5 Exthera Latest Developments
11.20 Flash Therapeutics
11.20.1 Flash Therapeutics Company Information
11.20.2 Flash Therapeutics Viral Vector Manufacturing for Gene Therapy Product Offered
11.20.3 Flash Therapeutics Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Flash Therapeutics Main Business Overview
11.20.5 Flash Therapeutics Latest Developments
11.21 VIVEBiotech
11.21.1 VIVEBiotech Company Information
11.21.2 VIVEBiotech Viral Vector Manufacturing for Gene Therapy Product Offered
11.21.3 VIVEBiotech Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.21.4 VIVEBiotech Main Business Overview
11.21.5 VIVEBiotech Latest Developments
11.22 FinVector
11.22.1 FinVector Company Information
11.22.2 FinVector Viral Vector Manufacturing for Gene Therapy Product Offered
11.22.3 FinVector Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.22.4 FinVector Main Business Overview
11.22.5 FinVector Latest Developments
11.23 Eurogentec
11.23.1 Eurogentec Company Information
11.23.2 Eurogentec Viral Vector Manufacturing for Gene Therapy Product Offered
11.23.3 Eurogentec Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.23.4 Eurogentec Main Business Overview
11.23.5 Eurogentec Latest Developments
11.24 VGXI
11.24.1 VGXI Company Information
11.24.2 VGXI Viral Vector Manufacturing for Gene Therapy Product Offered
11.24.3 VGXI Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.24.4 VGXI Main Business Overview
11.24.5 VGXI Latest Developments
11.25 GenScript ProBio
11.25.1 GenScript ProBio Company Information
11.25.2 GenScript ProBio Viral Vector Manufacturing for Gene Therapy Product Offered
11.25.3 GenScript ProBio Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.25.4 GenScript ProBio Main Business Overview
11.25.5 GenScript ProBio Latest Developments
11.26 EurekaBio
11.26.1 EurekaBio Company Information
11.26.2 EurekaBio Viral Vector Manufacturing for Gene Therapy Product Offered
11.26.3 EurekaBio Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.26.4 EurekaBio Main Business Overview
11.26.5 EurekaBio Latest Developments
11.27 Obio Technology
11.27.1 Obio Technology Company Information
11.27.2 Obio Technology Viral Vector Manufacturing for Gene Therapy Product Offered
11.27.3 Obio Technology Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.27.4 Obio Technology Main Business Overview
11.27.5 Obio Technology Latest Developments
11.28 GeneSail Biotech
11.28.1 GeneSail Biotech Company Information
11.28.2 GeneSail Biotech Viral Vector Manufacturing for Gene Therapy Product Offered
11.28.3 GeneSail Biotech Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.28.4 GeneSail Biotech Main Business Overview
11.28.5 GeneSail Biotech Latest Developments
11.29 VectorBuilder
11.29.1 VectorBuilder Company Information
11.29.2 VectorBuilder Viral Vector Manufacturing for Gene Therapy Product Offered
11.29.3 VectorBuilder Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.29.4 VectorBuilder Main Business Overview
11.29.5 VectorBuilder Latest Developments
11.30 WuXi ATU
11.30.1 WuXi ATU Company Information
11.30.2 WuXi ATU Viral Vector Manufacturing for Gene Therapy Product Offered
11.30.3 WuXi ATU Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.30.4 WuXi ATU Main Business Overview
11.30.5 WuXi ATU Latest Developments
11.31 Ubrigene
11.31.1 Ubrigene Company Information
11.31.2 Ubrigene Viral Vector Manufacturing for Gene Therapy Product Offered
11.31.3 Ubrigene Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.31.4 Ubrigene Main Business Overview
11.31.5 Ubrigene Latest Developments
11.32 Porton Biologics
11.32.1 Porton Biologics Company Information
11.32.2 Porton Biologics Viral Vector Manufacturing for Gene Therapy Product Offered
11.32.3 Porton Biologics Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.32.4 Porton Biologics Main Business Overview
11.32.5 Porton Biologics Latest Developments
11.33 Pharmaron
11.33.1 Pharmaron Company Information
11.33.2 Pharmaron Viral Vector Manufacturing for Gene Therapy Product Offered
11.33.3 Pharmaron Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.33.4 Pharmaron Main Business Overview
11.33.5 Pharmaron Latest Developments
11.34 PackGene Biotechnology
11.34.1 PackGene Biotechnology Company Information
11.34.2 PackGene Biotechnology Viral Vector Manufacturing for Gene Therapy Product Offered
11.34.3 PackGene Biotechnology Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.34.4 PackGene Biotechnology Main Business Overview
11.34.5 PackGene Biotechnology Latest Developments
11.35 Hillgene
11.35.1 Hillgene Company Information
11.35.2 Hillgene Viral Vector Manufacturing for Gene Therapy Product Offered
11.35.3 Hillgene Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.35.4 Hillgene Main Business Overview
11.35.5 Hillgene Latest Developments
11.36 Asymchem
11.36.1 Asymchem Company Information
11.36.2 Asymchem Viral Vector Manufacturing for Gene Therapy Product Offered
11.36.3 Asymchem Viral Vector Manufacturing for Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.36.4 Asymchem Main Business Overview
11.36.5 Asymchem Latest Developments
12 Research Findings and Conclusion
*If Applicable.
